Healthcare Capital Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Wilmington, Delaware.
IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/24/2022 | $18.00 | Buy | Ladenburg Thalmann |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Ladenburg Thalmann initiated coverage of Healthcare Capital with a rating of Buy and set a new price target of $18.00
25-NSE - Healthcare Capital Corp/DE (0001822935) (Subject)
8-K - Healthcare Capital Corp/DE (0001822935) (Filer)
425 - Healthcare Capital Corp/DE (0001822935) (Subject)
8-K - Healthcare Capital Corp/DE (0001822935) (Filer)
425 - Healthcare Capital Corp/DE (0001822935) (Subject)
8-K - Healthcare Capital Corp/DE (0001822935) (Filer)
425 - Healthcare Capital Corp/DE (0001822935) (Subject)
8-K - Healthcare Capital Corp/DE (0001822935) (Filer)
425 - Healthcare Capital Corp/DE (0001822935) (Subject)
8-K - Healthcare Capital Corp/DE (0001822935) (Filer)
Fastest customizable press release news feed in the world
JERUSALEM and WILMINGTON, Del., March 7, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, and Healthcare Capital Corp. (NASDAQ:HCCC) ("HCCC"), a special purpose acquisition company, announced today the successful closing of the previously announced business combination (the "Business Combination"). The combined company will continue to be led by Alpha Tau's existing management team. Alpha Tau's ordinary shares and warrants are expected to begin trading on Tuesday, March 8, 2022, on Nasdaq under the ticker symbols "DRTS" and "DRTSW," respectively. The transaction, and the various proposals giving effect ther
NEW YORK and JERUSALEM, ISRAEL , Feb. 22, 2022 (GLOBE NEWSWIRE) -- Healthcare Capital Corp. (NASDAQ:HCCC, HCCCW, and HCCCU))) ("HCCC") and Alpha Tau Medical Ltd. ("Alpha Tau"), an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors, today announced that in its special meeting held on February 18, 2022, HCCC's stockholders voted to approve the previously announced proposed business combination (the "Business Combination") of HCCC and Alpha Tau. Approximately 94.57% of the votes cast at the meeting, representing approximately 65.64% of HCCC's outstanding shares as of the record date, voted
NEW YORK, NY, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Healthcare Capital Corp. (NASDAQ:HCCC, HCCCW, and HCCCU))) ("HCCC") today announced that on February 18, 2022, it convened and then adjourned, without conducting any other business, its special meeting of stockholders (the "Special Meeting"). The Special Meeting has been adjourned until February 18, 2022 at 4:00p.m. Eastern Time (the "Adjournment"). The Special Meeting is being held to approve the business combination (the "Business Combination") with Alpha Tau Medical Ltd. ("Alpha Tau") and related proposals, as described in HCCC's definitive proxy statement filed with the Securities and Exchange Commission ("SEC") on January 14, 2022. The
NEW YORK, NY, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Healthcare Capital Corp. (NASDAQ:HCCC, HCCCW, and HCCCU))) ("HCCC") today announced that on February 15, 2022 it convened and then adjourned, without conducting any other business, its special meeting of stockholders (the "Special Meeting"). The Special Meeting has been adjourned until February 18, 2022 at 10:00 a.m. Eastern Time (the "Adjournment"). The Special Meeting is being held to approve the business combination (the "Business Combination") with Alpha Tau Medical Ltd. ("Alpha Tau") and related proposals, as described in HCCC's definitive proxy statement filed with the Securities and Exchange Commission ("SEC") on January 14, 2022. Th
JERUSALEM, Jan. 20, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that it has signed a sponsored research agreement with investigators at The University of Texas MD Anderson Cancer Center ("MD Anderson") to evaluate potential immune stimulation by combining Alpha DaRT™ with DNA-repair inhibitors and immune checkpoint inhibitors for the treatment of breast tumors. The study will be led by Gabriel Sawakuchi, Ph.D., Associate Professor of Radiation Physics, and Simona Shaitelman, M.D., Associate Professor of Radiation Oncology at MD Anderson, together with Alpha Tau's translational research
Special Meeting Scheduled for February 15, 2022 The combined company will be named Alpha Tau Medical Ltd. and remain listed on the NASDAQ under ticker DRTS NEW YORK, New York and JERUSALEM, Israel, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Healthcare Capital Corp (NASDAQ:HCCC, HCCCW, and HCCCU))) ("HCCC") today announced that on January 12, 2022, the U.S. Securities and Exchange Commission ("SEC") declared effective the Registration Statement on Form F-4 (as amended, the "Registration Statement") filed by Alpha Tau Medical Ltd. ("Alpha Tau"), which includes a definitive proxy statement/prospectus in connection with HCCC's special meeting of stockholders (the "Spec
JERUSALEM, Jan. 10, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that all ten patients in its US multi-center pilot trial of the Alpha DaRT for malignant skin & soft tissue cancers have reached the secondary endpoint for measurement of tumor response. The study met its primary feasibility endpoint, as all patients had successful delivery of radiation by Alpha DaRT. At approximately 12 weeks, all ten tumors demonstrated a complete response, defined as disappearance of the treated tumor, as measured using RECIST v.1.1 criteria, and the safety profile has been consistent with the company's
JERUSALEM, Jan. 3, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that it has been notified by HekaBio K.K., its clinical trial partner in Japan, that recruitment has been completed in its open-label multi-center pivotal study evaluating the Alpha DaRT in Japanese patients with recurrent Head & Neck cancer after radiotherapy. HekaBio has reported that preliminary results of this trial are highly encouraging, and that it will continue compilation and analysis of the data in
JERUSALEM, Nov. 3, 2021 /PRNewswire/ -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced today that it has enrolled its first patient in the combination study of Alpha DaRT and pembrolizumab (Keytruda®) at Hadassah Medical Center in Jerusalem, Israel. The clinical trial is designed to test the benefit of the Alpha DaRT in combination with pembrolizumab, an immunotherapy drug, for the treatment of recurrent unresectable or metastatic squamous cell carcinoma of the head and neck. The primary objective of the study is to evaluate efficacy of the combination, as measured by the confirmed Best Overall Response rate dete
JERUSALEM, Oct. 25, 2021 /PRNewswire/ -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced today that its US pilot trial for skin cancer has completed enrollment as planned. This announcement comes less than four months after the first patient was recruited into the trial in July 2021. Alpha DaRT sources were successfully implanted into all patients and then removed two to three weeks later as scheduled, and no serious adverse events related to the Alpha DaRT were noted at the time of removal. As such, the trial has met its first primary objective, in demonstrating feasibility of successful delivery of the Alpha DaRT. W
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Healthcare Capital Corp/DE (0001822935) (Issuer)
4 - VISION HYDROGEN Corp (0001676580) (Issuer)
4 - VISION HYDROGEN Corp (0001676580) (Issuer)
4 - VISION HYDROGEN Corp (0001676580) (Issuer)
4 - VISION HYDROGEN Corp (0001676580) (Issuer)
This live feed shows all institutional transactions in real time.
SC 13G/A - Healthcare Capital Corp/DE (0001822935) (Subject)
SC 13G - Healthcare Capital Corp/DE (0001822935) (Subject)
SC 13G - Healthcare Capital Corp/DE (0001822935) (Subject)
SC 13G/A - Healthcare Capital Corp/DE (0001822935) (Subject)
SC 13G/A - Healthcare Capital Corp/DE (0001822935) (Subject)
SC 13G - Healthcare Capital Corp/DE (0001822935) (Subject)
SC 13G/A - Healthcare Capital Corp/DE (0001822935) (Subject)
SC 13G - Healthcare Capital Corp/DE (0001822935) (Subject)
SC 13G/A - Healthcare Capital Corp/DE (0001822935) (Subject)
SC 13D/A - VISION HYDROGEN Corp (0001676580) (Subject)